Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
NATO Chief Tries to Ease Trump Alliance Dispute 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
Trump Administration Rejects Claims of Rift Between JD Vance and Marco Rubio on Iran Policy 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Crimea Power Outage After Ukrainian Drone Attack, Russian Authorities Say 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
ICC Judges Sue Trump Administration Over Sanctions, Calling Measures Unlawful 
Iran Strait of Hormuz Tensions Rise After Ship Attack Delays IMO Escort Mission 
Iran Attack in Strait of Hormuz Pushes Oil Prices Higher 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
President Donald Trump has announced a new agreement with UK-based pharmaceutical giant AstraZeneca, following a similar deal with Pfizer, aimed at cutting prescription drug prices in the United States. Under the pact, AstraZeneca will provide certain medicines to the U.S. Medicaid health program at discounted rates in exchange for relief from import tariffs, marking another step in the administration’s push to lower healthcare costs.
The deal forms part of the White House’s broader strategy to pressure major drugmakers to align U.S. prices with those in other developed nations, where patients often pay nearly three times less. In July, Trump sent letters to 17 leading pharmaceutical companies urging them to reduce prices or face steep tariffs. AstraZeneca and Pfizer are the first to comply, setting the stage for future negotiations.
AstraZeneca CEO Pascal Soriot revealed that the company will offer select drugs at up to 80% off their list prices through the upcoming TrumpRx online platform. In return, the firm will receive a three-year tariff exemption to support its plan to localize more of its production in the U.S. Soriot emphasized AstraZeneca’s growing American footprint, noting a $50 billion investment in U.S. manufacturing and R&D by 2030, including a massive new site in Virginia.
While the initiative may ease costs for Medicaid, experts remain skeptical about its broader impact. Northwestern University professor Craig Garthwaite noted that Medicaid already benefits from the nation’s lowest drug prices, suggesting limited savings. Boston University’s Rena Conti added that while the agreement benefits pharmaceutical firms, it offers little relief to Americans struggling with high out-of-pocket costs.
AstraZeneca’s latest moves reflect its effort to strengthen ties with Washington while expanding U.S. operations, including plans to list its shares on U.S. markets and sell some drugs directly to cash-paying patients at significant discounts.
